Cencora, Inc. (NYSE:COR) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Cencora, Inc. (NYSE:COR) have been given a consensus recommendation of “Moderate Buy” by the fourteen brokerages that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $403.1667.

COR has been the topic of a number of analyst reports. Bank of America dropped their price target on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Morgan Stanley set a $380.00 target price on shares of Cencora in a research report on Tuesday. Wells Fargo & Company boosted their price target on shares of Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Finally, Leerink Partners restated an “outperform” rating on shares of Cencora in a research report on Tuesday.

Cencora Stock Performance

COR opened at $332.06 on Friday. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The firm has a market cap of $64.59 billion, a PE ratio of 39.91, a P/E/G ratio of 1.51 and a beta of 0.68. The business has a fifty day simple moving average of $355.08 and a 200-day simple moving average of $339.36. Cencora has a fifty-two week low of $264.33 and a fifty-two week high of $377.54.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same period in the previous year, the firm earned $3.73 earnings per share. Cencora’s revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, equities analysts predict that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s payout ratio is 28.85%.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares in the company, valued at $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.38% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of COR. Kemnay Advisory Services Inc. purchased a new stake in Cencora in the 4th quarter worth about $25,000. Oakworth Capital Inc. purchased a new position in Cencora during the 4th quarter valued at about $26,000. Elyxium Wealth LLC acquired a new position in shares of Cencora in the 4th quarter valued at about $27,000. Archer Investment Corp increased its holdings in shares of Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares during the period. Finally, Motiv8 Investments LLC purchased a new stake in shares of Cencora in the fourth quarter worth approximately $29,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.